The quest to cure spinal muscular atrophy still has many years to go, but the signs of progress are unmistakable
A Closer Look: SMA Slideshow
August is often referred to as Spinal Muscular Atrophy (SMA) Awareness Month, but for MDA, work on finding treatments for this degenerative disease — and providing assistance to individuals and families affected by it — is a year-round event.
Today, research aimed at slowing, stopping or even preventing spinal muscular atrophy (SMA) is advancing with more speed...
A program that prepares young scientists for careers in drug development has awarded a grant for the study of muscle repair-boosting compounds
Christopher Penton recently completed his doctorate (Ph.D.) in integrated biomedical sciences at Ohio State University in Columbus.
Research progress in one disease can lead to progress in other diseases — and MDA’s latest round of grants seek to leverage this potential
In its summer 2013 round of research grant awards, the Muscular Dystrophy Association aims to catalyze research progress in a dozen neuromuscular diseases, with an eye toward applying that knowledge to related muscle diseases, as well.
“A large number of our grants are investigating new therapeutic technologies,” notes Jane Larkindale, MDA's vice president of research. “These are 'platform'...
MDA grant will support a study of prednisone in 25 boys with Duchenne muscular dystrophy who are less than 2½ years old
Pediatric neurologist Anne Connolly has received an MDA grant to study the effects of prednisone on Duchenne muscular dystrophy in very young children.
MDA has awarded a grant to Anne Connolly, a pediatric neurologist at Washington University in St.
The conference provided opportunities for information-sharing and collaboration among scientific professionals from many disciplines
Turning neuromuscular disease research into treatments as quickly as possible was the overarching theme of dozens of formal presentations, nearly 200 scientific posters and countless informal conversations at the MDA Scientific Conference, April 21-24, 2013.
A palpable sense of excitement pervaded the sold-out event thanks to the unprecedented number of experimental treatments in clinical trials...
Many MDA grants for research in myasthenia gravis aim to prevent the immune system from attacking needed muscle proteins while allowing it to fight infection
It can start with nothing more than a drooping eyelid or a slight slurring of speech, either of which can come and go and improve with rest. But it can progress, often gradually over weeks or months, to affect all the voluntary muscles, including those controlling breathing. Weakness may be minimal early in the morning after a good night's sleep and worsen throughout the day, especially after...
A $1.2 million MDA grant will help move an experimental cell-penetrating treatment for myotubular myopathy toward human testing
The Muscular Dystrophy Association has awarded $1,195,762 over two years to biotechnology company Valerion Therapeutics (formerly 4s3 Bioscience) for development of a treatment for myotubular myopathy (MTM).